Searchable abstracts of presentations at key conferences in endocrinology

ea0090p69 | Diabetes, Obesity, Metabolism and Nutrition | ECE2023

Effects of Glucagon-Like Peptide-1 Analogs on Sexual Desire: A randomized, double-blind, placebo-controlled crossover trial

Lengsfeld Sophia , Hasenbohler Flavia , Probst Leila , Baur Fabienne , Emara Yara , Bathelt Cemile , Werlen Laura , Vogt Deborah , Caviezel Brida , Vukajlovic Tanja , Christ-Crain Mirjam , Winzeler Bettina

Background: GLP-1 analogs are prescribed for diabetes and obesity due to their well-known insulinotropic, satiation-promoting and appetite-suppressant effects. Several studies also investigated the effects of GLP-1 analogs on reward to addictive drugs such as alcohol, nicotine and cocaine. Pre-clinical studies suggest that sexual desire, as another type of natural reward, could also be affected by GLP-1 analogs. Since sexuality is a very important aspect of human wellbeing and...

ea0099p31 | Adrenal and Cardiovascular Endocrinology | ECE2024

Blood pressure changes during smoking cessation on dulaglutide and placebo treatment – a secondary analysis of the randomized, double-blind, placebo-controlled SKIP trial

Julia Beck , Hasenbohler Flavia , Lengsfeld Sophia , Burkard Thilo , Meienberg Andrea , Jeanloz Nica , Vukajlovic Tanja , Bologna Katja , Bathelt Cemile , Vogt Deborah , Werlen Laura , Christ-Crain Mirjam , Winzeler Bettina

Objective: Smoking is an established major risk for atherosclerosis and cardiovascular mortality. However, the impact of smoking cessation on blood pressure remains controversial. Despite strong evidence linking smoking cessation to reduced cardiovascular risk, conflicting studies suggest potential increases in blood pressure after smoking cessation. Post cessational weight gain may contribute to these confliciting findings. We have recently shown that the glucagon-like peptid...